Dr. Nitin V. Sheth, Ph.D.
President & CEO, Indicus Pharma

Nitin Sheth, Ph.D., is a President & CEO of Indicus Pharma and one of the founding members of a startup organization. Dr. Sheth has twenty years of progressive leadership experience in Pharmaceutical Research and Development organization to carry out product development, process & validation activities and global product development & technology transfer activities. During these years, he had successfully developed immediate as well as controlled release products that resulted in approximately 90+ ANDA submissions (includes P-IV & first to file submissions). Dr. Sheth is specialized in the development of oral controlled release products and received number of worldwide formulation patents on CR product development. He is knowledgeable in US FDA requirements of ANDA submissions and US generic market dynamics.

Prior to founding this company, Dr. Sheth served as Vice President, Research & Development for Eon Labs from April 2002 to January 2005 where he was responsible for entire R & D efforts of Eon Labs. Dr. Sheth served as Director, Product Development for Ivax Pharmaceuticals, Inc. from March 1998 to April 2002 where he was responsible for developing generic products. From September 1993 to March 1998, he was Manager, Product Development for Zenith Labs and later named as Zenith Goldline Pharmaceuticals, Inc. (a wholly owned subsidiary of IVAX Corporation). Dr. Sheth held positions with American Cynamid Co. in Formulations Research Division from June 1986 to August 1993, including Group Leader of Formulation Development, where he was responsible for research and development activities on new as well as marketed products. Dr. Sheth received his B.S. degree in Pharmacy from University of Bombay and M.S. degree in Pharmaceutics from Gujarat University in India. Dr. Sheth received his Ph.D. in Pharmaceutics from University of Pacific, California. From 1983 to 1986, Dr. Sheth worked as a postdoctoral research fellow at University of Utah under Dr. Higuchi & Dr. Spruance on Topical Delivery of Antivirals.